Lates News

According to the AI report, Open Source Securities issued a research report on March 31, giving Haier Biological (688139.SH) a "buy" rating. The rating reasons mainly include: 1) overseas markets are thriving, while domestic markets are steadily recovering; 2) internal research and innovation promote development, while external expansion, mergers and acquisitions integrate platforms. (Daily Economic News)